产品
编 号：F296639
分子式：C3H5Na2O4P
分子量：182.02
分子式：C3H5Na2O4P
分子量：182.02
产品类型
规格
价格
是否有货
500mg
400
In-stock
结构图
CAS No: 26016-99-9
产品详情
生物活性：
Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria.
体内研究：
Fosfomycin sodium (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes.Pharmacokinetic of Fosfomycin sodium in RatsDibekacin Dose (mg)Vdss (l/kg)β (min-1)T1/2 (min)Urinary recovery (%)
300.2610.024428.485
Animal Model:Fischer 344 rats
Dosage:320 mg/kg
Administration:Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days
Result:Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.
Animal Model:Dehydrated Wistar rat with acute renal failure (8-week-old)
Dosage:120 mg/kg
Administration:Intravenous injection; once
Result:Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters.Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.
体外研究：
Fosfomycin sodium is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis.Fosfomycin sodium has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%.Fosfomycin sodium displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses.
Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria.
体内研究：
Fosfomycin sodium (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes.Pharmacokinetic of Fosfomycin sodium in RatsDibekacin Dose (mg)Vdss (l/kg)β (min-1)T1/2 (min)Urinary recovery (%)
300.2610.024428.485
Animal Model:Fischer 344 rats
Dosage:320 mg/kg
Administration:Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days
Result:Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.
Animal Model:Dehydrated Wistar rat with acute renal failure (8-week-old)
Dosage:120 mg/kg
Administration:Intravenous injection; once
Result:Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters.Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.
体外研究：
Fosfomycin sodium is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis.Fosfomycin sodium has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%.Fosfomycin sodium displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备